小分子新药智创未来｜
“华先药智汇”2022首届学术论坛圆满召开
"Smart Innovation for the Future of Small Molecule New Drugs
First“HwaGen PharmTec Wisdom Pool”Academic Forum2022Held
导语：
Background:
At present,the development of new drugs in China has begun to move towards"global innovation",among which small molecule drug innovation is still the mainstream.In2020,FDA approved53new drugs,including38new molecular entities,accounting for71.7%;in2021,FDA approved a total of50new drugs,including36new molecular entities,accounting for72%;by2021,Shenzhen has a total of more than150enterprises and scientific research institutions,with1387applications for small molecule new drugs,showing an upward trend in both quantity and quality compared with the previous year.
立学术之风范，探“小分子”之始归。5月28日下午，华先药智汇2022首届学术论坛以“小分子新药智创未来”作为主题掀开首篇。坪山区委常委、副区长叶青云，南方科技大学坪山生物医药研究院院长张绪穆院士，兴湾生物公司首席科学家张丹院士，广东省生物医药创新技术协会执行会长朱少璇，贝壳大学名誉校长朱迅，深圳清华大学研究院副院长潘泽生，坪山区科技创新局局长黄鸣，坪山区编办副主任孙秋澄，坪山区委组织部（区人才工作局）副局长饶巍,出席了此次论坛。来自业界的多位资深专家共同见证了华先医药一站式CRO/CDMO平台发布仪式，并探讨小分子创新药的未来，围绕小分子新药在新冠抗疫中的重要作用及创新药企在当前形势下如何更好地融资引才等话题展开圆桌讨论。本次论坛同步进行了线上直播，吸引了近两万人在线参与及互动。
On the afternoon of May28,the first academic Forum of HwaGen PharmaTec Wisdom Pool2022kicked off with the theme of"Smart Innovation for the Future of Small Molecule New Drugs".
Ye Qingyun,standing member of Pingshan District Party Committee and deputy head of Pingshan District;Zhang Xumu,academician,the dean of the Southern University of Science and Technology Pingshan Bio-medical Research Institute;Zhang Dan,academician,chief scientific officer of Shenzhen Xingwan Biotech Co.,Ltd;Zhu Shaoxuan,executive President of Guangdong Biomedical Innovation Technology Association,Zhu Xun,honorary president of Bio-tech University,Pan Zesheng,deputy dean of Shenzhen Research Institute of Tsinghua University;Huang Ming,director of the Bureau of Science,Technology and Innovation of Pingshan;Sun Qiucheng,deputy director of Pingshan Commission Office for Public Sector Reform;Rao Wei,deputy director of the organization department of Pingshan District Party Committee(Pingshan District Talent Bureau)attended this forum,a number of senior experts from the industry witnessed the launch ceremony of HwaGen One-stop CRO/CDMO platform,and discussed the future of small molecule innovative drugs,the important role of small molecule new drugs in the fight against COVID-19,innovative pharmaceutical enterprises in the current situation how to better financing and recruit talents。The forum was simultaneously broadcast online,and10,000people watched the live broadcast online which attracted nearly20,000people participating and interacting online.
1华先医药一站式CRO/CDMO平台发布仪式
平台启动 研发赋能
华先医药联合创始人、董事长兼CEO叶伟平博士首先对华先医药一站式CRO/CDMO平台进行了展示。近年来华先医药始终聚焦于小分子新药CRO/CDMO服务，通过发挥创新工艺路线设计、生物酶催化、连续流微反应技术、AI+及连续自动化等五大技术平台优势，建设坪山总部研发基地、大亚湾中试基地、大亚湾生产基地，华东研发中心，上海商务中心五大基地，致力于服务客户，服务新药研发。同时，华先医药也将会保持技术创新性，提前布局高价值的新兴技术，展开面向全球性的商务合作，打造可持续、为创新药企提供高效率、高性价比的科技一站式CRO/CDMO平台。
【叶博汇报照片】
Part1Launch ceremony of HwaGen One-stop CRO/CDMO platform
【Platform Launched and R&D Value-added】Dr.Weiping Ye,co-founder,Chairman and CEO of HwaGen,first presented the one-stop CRO/CDMO platform.
In recent years,HwaGen has always been focused on the small molecule drugs CRO/CDMO services,by giving full play to the advantages of innovative process route design,biological enzyme catalysis,continuous flow micro-reaction technology,AI+and continuous automation,five bases have been built,Pingshan Headquarters R&D base,Daya Bay pilot base,Daya Bay production Base,East China R&D Center and Shanghai Business Center committed to serving customers,service new drug research and development.At the same time,HwaGen Will also maintain technological innovation,advance the layout of high-value emerging technologies,carry out global business cooperation,and create a sustainable,efficient and cost-effective one-stop CRO/CDMO technology platform for innovative pharmaceutical enterprises.
华先医药联合创始人、国际商务负责人Andrew Phillis博士也通过视频与现场连线，阐述华先医药将持续深耕海外客户，把握CDMO转移红利，并在北美/欧洲落地商务-研发-生产基地的战略布局。
【安杰视频照片】
Dr.Andrew Phillis,co-founder and head of international business of HwaGen,also explained the strategic layout of HwaGen that it will continue to cultivate overseas customers,seize the CDMO transfer opportunities,and set up a business-R&D-production base in North America/Europe.
随后，会上举行了华先医药一站式CRO/CDMO平台发布的启动仪式。
【启动仪式合影】
Later,the launch ceremony of the One-stop CRO/CDMO platform was held at the forum.
接着，坪山区委常委、副区长叶青云在发布仪式中讲话，他提到，华先医药一站式CRO/CDMO平台建设是深圳坪山生物医药产业发展的一件大事和喜事，对坪山率先建设国际先进的生物医药科技产业城，助力全市乃至粤港澳湾区医药产业高质量发展具有重要意义。本届论坛的召开将会更好地提升小分子新药研发公司与CRO/CDMO服务平台公司之间的密切合作，相信未来在叶博士的带领下，华先医药将会日益发展壮大，一体化服务平台建设将会越来越完善。
【常委讲话照片】
Then,Ye Qingyun,standing member of Pingshan District Party Committee and deputy head of Pingshan District delivered speech in the launch,he noted the construction of one-stop CRO/CDMO platform is a great event and happy event in the development of Shenzhen Pingshan biomedical industry,it is of great significance for Pingshan to take the lead in building an international advanced biomedical technology industry city,and to help the city and even the Guangdong-Hong Kong-Macao Greater Bay Area to develop the pharmaceutical industry with high quality.The convening of this forum will further enhance the close cooperation between small molecule drug discovery companies and CRO/CDMO service platform companies.It is believed that under the leadership of Dr.Ye in the future,HwaGen will grow stronger and stronger day by day,and the construction of integrated service platform will be more and more perfect.
产学研用 创新驱动
华先医药在坚定不移地推进战略业务布局的同时，也在积极地探索和其它高校机构产学研合作整合创新的发展模式。会上，华先医药与深圳清华大学研究院共建的联合创新中心被揭牌启用。双方开展深度合作，目前已经成立合资公司，致力于打造药代动力学平台、药效学成药性评价研究平台、药物毒理学评价平台等综合服务能力。此外，还有华先医药与南方科技大学坪山生物医药研究院共建的联合实验室、华先医药与华南师范大学共建的广东省联合培养研究生示范基地、湾区新药汇秘书长单位、贝壳学社校友会第二届会长单位均被揭牌启用。
【系列揭牌照片】
Industry-University-Research,Innovation drives
HwaGen is unswervingly promoting strategic business layout,at the same time,it is also actively exploring the development mode of industry-university-research cooperation and integration innovation with other institutions.The joint innovation center jointly built by HwaGen and Research Institute of Tsinghua University in Shenzhen was inaugurated,the two parties have carried out in-depth cooperation and have established a joint venture company,which is committed to building comprehensive service capabilities such as pharmacokinetic platform,pharmacodynamics drug-forming evaluation and research platform,and drug toxicology evaluation platform.In addition,the joint laboratory built by HwaGen and Pingshan Institute of Biological Medicine of Southern University of Science and Technology,the Guangdong Province joint Postgraduate Training demonstration base built by HwaGen and South China Normal University,the Secretary General unit of Bay Area New Drug Association,and the second president unit of Bio-tech Association have all been opened.
智库引擎 高效蓄力
为了更好地推进一体化服务平台建设，华先医药成立了“科学顾问委员会”与“战略顾问委员会”。会上，新加坡科学院陈俊丰（Tan Choon Hong）院士以及俄罗斯工程院张绪穆院士受聘作为“科学顾问委员会”的顾问成员；埃格林医药董事长杜涛博士与国家重大人才工程创业导师曹进受聘作为“战略顾问委员会”的顾问成员。顾问委员会将在后续华先医药的企业战略规划布局上建言献策，为华先医药不断完善在绿色CRO/CDMO领域的上下游产业生态圈奠定基础。
【系列授聘照片】
Think-tank engine efficiently builds up strength.
In order to better promote the construction of integrated service platform,HwaGen has established"Scientific Advisory Committee"and"Strategic Advisory Committee".Tan Choon Hong,academician of the Singapore Academy of Sciences,Zhang Xumu,academician of the Russian Academy of Engineering were appointed as advisory members of the"Scientific Advisory Board".Dr.Tao Du,Chairman of Evergreen Pharmaceutical Co.,Ltd,Cao Jin,national major Talents Project entrepreneurship mentor were engaged as advisory members of the Strategic Advisory Board.The advisory committee will make suggestions on the subsequent corporate strategic planning and layout of HwaGen,laying a foundation for HwaGen to continuously improve the upstream and downstream industry ecosystem in the field of CRO/CDMO.
资源耦合 共享共赢
会上，华先医药还与多家合作伙伴签署了战略合作协议。未来将会秉承着协同创新、聚力前行、合作共赢的理念，共同谱写新的篇章！
Resource coupling,Shared win-win
HwaGen also signed strategic cooperation agreements with a number of partners.In the future,we will adhere to the concept of collaborative innovation,gathering strength and win-win cooperation,and write a new chapter together!
【埃格林医药签约】
深圳埃格林医药有限公司是以量子计算和端到端AI技术为核心的全新高效国际化创新药企。于2019年8月在中国深圳成立，致力于满足临床需求、实现临床价值，惠泽全球患者。
Shenzhen Evergreen Pharmaceutical Co.,Ltd.is a new and efficient international innovative pharmaceutical enterprise with quantum computing and end-to-end AI technology as its core.Established in August2019in Shenzhen,China,the company is committed to meeting clinical needs,realizing clinical value and benefiting patients around the world.
【艾欣达伟签约】
深圳艾欣达伟医药科技有限公司位于深圳市坪山区，创立于2017年，是一家拥有原创能力、专注于拥有广阔市场前景的广谱靶向抗肿瘤创新药研发的高新医药科技企业。
Shenzhen Ascentawits Pharmaceutical Technology Co.,Ltd.is located in Pingshan District,Shenzhen city,founded in2017,is a high-tech pharmaceutical technology enterprise with original ability,focusing on the development of broad spectrum targeted anti-tumor innovative drugs with broad market prospects.
【启蓝生物签约】
深圳启蓝生物医药科技有限公司是一家以合成多糖作为基础生物材料用于修饰小分子药、生物药以及发展全新给药系统（包括胶囊以及纳米脂肪粒LNP）的创新公司。
Shenzhen Qilan Biomedical Technology Co.,Ltd.is an innovative company that uses synthetic polysaccharides as basic biomaterials to modify small molecule drugs and biological drugs and develop new drug delivery systems(including capsules and nano-sized fat particles LNP).
【PPMU签约】
制药项目管理联盟是中国首个专注于医药行业项目管理的全国性联盟组织，由国内多家头部药企、新锐研发机构等联合发起。旨在为真正有意将一次性工作作为项目管理的企业和个人提供学习交流共享平台，帮助企业降本增效，推动行业卓越发展。
Pharmaceutical Project Management Alliance is the first national alliance organization focusing on pharmaceutical industry project management in China,which is jointly initiated by a number of domestic leading pharmaceutical enterprises and cutting-edge research and development institutions.It aims to provide a learning exchange and sharing platform for enterprises and individuals who are really interested in one-off work as project management,helping enterprises reduce costs and increase efficiency,and promoting the excellent development of the industry.
【深圳市坪山区产业资本投资有限公司签约】
深圳市坪山区产业资本投资有限公司成立于2021年，是坪山区人民政府设立的专注金融资本管理的独资国有企业，以提升国有资本运营效率、提高国有资本回报为发展目标，旨在成为坪山区推动产业转型升级与创新驱动发展的关键抓手和重要载体。
Shenzhen Pingshan Industry Capital Investment Co.,Ltd.,founded in2021,which is wholly state-owned enterprises and set up by Pingshan District people's government focusing on financial capital management,to improve the efficiency of state-owned capital operation and the return of state-owned capital as the development goal,aims to become a key driver and carrier for promoting industrial transformation and upgrading and innovation-driven development in Pingshan District.
【南方科技大学坪山生物医药研究院签约】
南方科技大学坪山生物医药研究院由南方科技大学与坪山区人民政府合作共建，主要研发方向为药物化学、抗肿瘤及抗病毒小分子药物研发、手性药物绿色合成等。
Pingshan Institute of Biomedicine of Southern University of Science and Technology is jointly established by Southern University of Science and Technology and Pingshan District People's Government,the main research and development directions are pharmaceutical chemistry,anti-tumor and anti-virus small molecule drug development,chiral drug green synthesis,etc.
【深福保签约】
由深福保运营管理的坪山生物医药创新产业园是深圳市政府为促进高成长性中小企业快速扩张而建设的大型生物产业载体，目前，园区企业在小分子药物开发、智能医疗器械研发等生物医药细分领域集聚了科技优势，在华南地区具有领先地位。
Pingshan Biomedical Innovation Industrial Park operated and managed by Shenfubao is a large-scale biological industry carrier built by Shenzhen municipal government to promote the rapid expansion of high-growth small and medium-sized enterprises.At present,enterprises in the park have gathered scientific and technological advantages in the development of small molecule drugs,intelligent medical devices and other bio-medical segmentation fields,and have a leading position in South China.
【转化中心签约】
深圳湾实验室坪山生物医药研发转化中心作为深圳湾实验室下设独立的二类事业单位，围绕抢抓粤港澳大湾区和深圳建设中国特色社会主义先行示范区“双区叠加”重大战略，推动建设新药研发平台、医药转化平台和公共技术服务平台。
华先医药将会与各合作单位协同创新、聚力前行、合作共赢，通过战略合作共同谱写新的篇章！
Shenzhen Bay Laboratory Pingshan Biomedical R&D and Transformation Center is an independent second-class public institution under Shenzhen Bay Laboratory,in accordance with the major strategy of developing the Guangdong-Hong Kong-Macao Greater Bay Area and Shenzhen into a pioneering demonstration zone of socialism with Chinese characteristics,we will promote the development of platforms for the research and development of new drugs,platforms for drug commercialization,and platforms for public technical services.
HwaGen will cooperate with all cooperative partners for collaborative innovation,convergence,win-win cooperation,and write a new chapter together through strategic cooperation
2.圆桌讨论一：小分子新药-新冠抗疫的最后一块拼图
深圳兴湾生物医药发展顾问有限公司首席科学家张丹院士主持了本场圆桌论坛。在场的嘉宾围绕小分子创新药的未来，小分子新冠药物在抗击防疫之战中的重要作用等话题进行了深度探讨。
小分子药物结构具有良好的空间分散性，长期临床使用的安全性、有效性等因素，使得小分子药物在研发过程及其它药物领域中表现出明显的优势，尤其在抗击新冠疫情方面，吉利德的RdRp抑制剂瑞德西韦、默沙东的RdRp抑制剂Molnupiravir、辉瑞的3CLp抑制剂Paxlovid等小分子新药发挥了巨大的优势，因疗效明显、服用方便、便于携带、成本较低等使其成为了抗新冠主流并在全球占据了较大的市场份额，中国、日本等国均相继开展抗新冠小分子新药的国际多中心临床试验。
【圆桌现场一】
Roundtable Discussion1:Small Molecule New Drug--the final market of the anti-COVID-19drugs.
Academician Zhang Dan,chief scientist of Shenzhen Xingwan Biomedical Development Consulting Co.,LTD.,chaired this roundtable forum.The panelists had in-depth discussions on the future of small molecule innovative drugs and the important role of small molecule COVID-19drugs in the fight against pandemic prevention.
Small molecule drug structure has good spatial dispersion,long-term clinical use of safety,effectiveness and other factors,so that small molecule drug research and development process and other drug fields show obvious advantages,especially in the fight against COVID-19,Remdesivir,Gilead's RdRp inhibitor,Molnupiravir,Merck's RdRp inhibitor,Paxlovid,Pfizer's3CLp inhibitor,these small molecule new drugs play a huge role,because of their obvious curative effect,convenient administration,portability and low cost,they have become the mainstream of anti-COVID-19and occupy a large market share in the world.China,Japan and other countries are conducting international multi-center clinical trials of small molecule new anti-COVID-19drugs.
3.圆桌讨论二：新冠疫情与资本寒冬下，创新药企的融资引才如何破局？
国家重大人才工程创业导师曹进导师担任本场圆桌论坛主持。创新药企的创始人，高管及投资人全方位地解析了在当前形势下，如何更好地获得资本的青睐，顺利获得融资，和人才引进的破局之道。
【圆桌现场二】
Roundtable Discussion2:Under the COVID-19and the capital winter,
how do the financing and talent recruiting of innovative pharmaceutical enterprises lead to break the situation?
Cao Jin,national major Talents Project entrepreneurship mentor hosts this round table forum.The founders,executives and investors of innovative pharmaceutical companies fully explained how to better obtain the favor of capital,smooth access to financing,and talent introduction in the current situation.
